TY - JOUR
T1 - Internationalization of read-across as a validated new approach method (NAM) for regulatory toxicology
AU - Rovida, Costanza
AU - Barton-Maclaren, Tara
AU - Benfenati, Emilio
AU - Caloni, Francesca
AU - Chandrasekera, Charu
AU - Chesne, Christophe
AU - Cronin, Mark T D
AU - De Knecht, Joop
AU - Dietrich, Daniel R
AU - Escher, Sylvia E
AU - Fitzpatrick, Suzanne
AU - Flannery, Brenna
AU - Herzler, Matthias
AU - Hougaard Bennekou, Susanne
AU - Hubesch, Bruno
AU - Kamp, Hennicke
AU - Kisitu, Jaffar
AU - Kleinstreuer, Nicole
AU - Kovarich, Simona
AU - Leist, Marcel
AU - Maertens, Alexandra
AU - Nugent, Kerry
AU - Pallocca, Giorgia
AU - Pastor, Manuel
AU - Patlewicz, Grace
AU - Pavan, Manuela
AU - Presgrave, Octavio
AU - Smirnova, Lena
AU - Schwarz, Michael
AU - Yamada, Takashi
AU - Hartung, Thomas
PY - 2020
Y1 - 2020
N2 - Read-across (RAx) translates available information from well-characterized chemicals to the substance for which there is a toxicological data gap. The OECD is working on case studies to probe general applicability of RAx, and several regulations (e.g. EU-REACH) already allow this procedure to be used to waive new in vivo tests. The decision to prepare a review on the state of the art of RAx as a tool for risk assessment for regulatory purposes was taken during a workshop with international experts in Ranco, Italy in July 2018. Three major issues were identified that need optimisation to allow a higher regulatory acceptance rate of the RAx procedure: (i) the definition of similarity of source and target, (ii) the translation of biological/toxicological activity of source to target, in the RAx procedure, and (iii) how to deal with issues of ADME that may differ between source and target. The use of new approach methodologies (NAM) was discussed as one of the most important innovations to improve the acceptability of RAx. At present, NAM data may be used to confirm chemical and toxicological similarity. In the future, the use of NAM may be broadened to fully characterize the hazard and toxicokinetic properties of RAx compounds. Concerning available guidance, documents on Good Read-Across Practice (GRAP) and on best practices to perform and evaluate the RAx process were identified. Here, in particular the RAx guidance, being worked out by the European Commission's H2020 project EU-ToxRisk, together with many external partners with regulatory experience, is given.
AB - Read-across (RAx) translates available information from well-characterized chemicals to the substance for which there is a toxicological data gap. The OECD is working on case studies to probe general applicability of RAx, and several regulations (e.g. EU-REACH) already allow this procedure to be used to waive new in vivo tests. The decision to prepare a review on the state of the art of RAx as a tool for risk assessment for regulatory purposes was taken during a workshop with international experts in Ranco, Italy in July 2018. Three major issues were identified that need optimisation to allow a higher regulatory acceptance rate of the RAx procedure: (i) the definition of similarity of source and target, (ii) the translation of biological/toxicological activity of source to target, in the RAx procedure, and (iii) how to deal with issues of ADME that may differ between source and target. The use of new approach methodologies (NAM) was discussed as one of the most important innovations to improve the acceptability of RAx. At present, NAM data may be used to confirm chemical and toxicological similarity. In the future, the use of NAM may be broadened to fully characterize the hazard and toxicokinetic properties of RAx compounds. Concerning available guidance, documents on Good Read-Across Practice (GRAP) and on best practices to perform and evaluate the RAx process were identified. Here, in particular the RAx guidance, being worked out by the European Commission's H2020 project EU-ToxRisk, together with many external partners with regulatory experience, is given.
U2 - 10.14573/altex.1912181
DO - 10.14573/altex.1912181
M3 - Journal article
C2 - 32369604
SN - 1868-596X
VL - 37
SP - 579
EP - 606
JO - A L T E X. Alternatives to Animal Experimentation
JF - A L T E X. Alternatives to Animal Experimentation
IS - 4
ER -